drugset / Trial / NCT00106288

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288

Phase 3 Completed 637 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.

Timeline

Start
2003-01
Primary completion
2005-12
Completion
2005-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amphotericin B Unknown 3 mg/kg
Subject Micafungin Peptide 2 mg/kg
Subject Micafungin Peptide 100 mg

Indications